Mednet
Behind every medicine is a person. And behind every person is a life shaped by more than their condition.
At Mednet, we see beyond the disease to the life around it. Because science alone doesn’t decide outcomes, life does.
How people engage with their health is shaped by the full human context behind every decision and behaviour: the physical reality of treatment, the emotional experience of living with a condition, and the mental processes that drive understanding, belief and routine.
This is the foundation of Making Health Whole™.
We design healthcare strategy and communications for these realities, so people feel confident to take control, stay on track, and achieve optimal outcomes.
From congresses and brand strategy to HCP education and patient engagement, we create connected experiences that reflect how people actually live with their health. Not ideal journeys, but real ones, where motivation fluctuates, information can overwhelm, and engagement can quietly break down.
By combining clinical rigour, behavioural insight and lived experience, we identify where engagement becomes fragile and design support that makes the next step easier than disengagement.
We design for engagement from the outset, shaping understanding, building confidence and supporting persistence over time.
Because when people are able to engage with their health, they are more likely to stay on track and persist with treatment. And when engagement is sustained, better outcomes follow.
Mednet. Whole Health. For Everyone.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Company Details
Latest Content from PMHub
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Press Releases | June 24, 2026 | Genesis Research Group
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...
Medscape Education to Showcase the Impact of Neurology CME at EAN 2026
Press Releases | June 23, 2026 | Medscape Education
Medscape Education, the leading global provider of continuing medical education (CME), has announced its agenda for the upcoming 12th Congress of the European Academy of Neurology (EAN) 2026 in Geneva,...
Designing Pharma Stands That People Actually Want to Step Onto
Press Releases | June 18, 2026 | Apex Events and Exhibitions
Exhibition halls are busy environments where delegates move quickly, often with limited time. For pharmaceutical companies, this presents a challenge: how do you create a stand that invites meaningful engagement...
Live Webinar | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
White Papers and Resources | June 18, 2026 | Inizio
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
The solution: Good localisation doesn’t feel translated
White Papers and Resources | June 18, 2026 | Cuttsy + Cuttsy
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Good Patient Partnership Guide 2026: Patient Journey Mapping with the Patient Community
White Papers and Resources | June 18, 2026 | Precision AQ
Patient insight gathering and journey mapping can inform and enhance decision making and initiatives across life sciences. The Good Patient Partnership Guide 2026 brings together practical guidance, real world examples...
Healthcare information is becoming easier to access. Trust isn’t.
White Papers and Resources | June 17, 2026 | Cuttsy + Cuttsy
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
White Papers and Resources | June 17, 2026 | Cuttsy + Cuttsy
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Press Releases | June 17, 2026 | Uniphar
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology...
Medscape Education Recognized With 2 Spring 2026 Digital Health Awards for Excellence in Clinical Education
Press Releases | June 16, 2026 | Medscape Education
Medscape Education has been recognized with 2 prestigious accolades at the Spring 2026 Digital Health Awards. The premier digital education platform earned a Gold Award for its PIONEER initiative in...